A serious disadvantage of preventing clot formation by using prostacyclin (PGI2) to inhibit thrombocyte function during dialysis is that there exists no rapidly measurable monitoring parameter. The “in vitro bleeding time” fin vitro BT) is a new method for measuring primary hemostasis in vitro. Five chronic dialysis patients each underwent two dialyses: 1) with conventional full heparinization, and 2) with the stable PGI2 analogue CG 4203 and additional “low-dose” heparin. The predialytic in vitro BT is longer than normal values and values 1 h after the end of dialysis. While heparin has no significant effect on the in vitro BT, CG 4203 prolongs it concentration-dependently. Infusing CG 4203 at a rate of 25 ng/kg/min, the in vitro BT is extended beyond the measurable range of 800 μl during the first approx. 150 min of dialysis. During the next approx. 90 min it steadily decreases.
CrowJ.W., DubrowA., SwartzR., CatoA., FlamenbaumW.Hemorrhage during hemodialysis: Flolan (prostacyclin) versus heparin. Abstract Book of the “6th Int Conf on Prostaglandins and Related Compounds”, Florence 1986; 46.
2.
MaurinN., BallmannM.Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin.Clin Nephrol1988; 30: 35–41.
3.
BornG.V.R.Aggregation of blood platelets by adenosine diphosphate and its reversal.Nature1962; 194: 927–9.
4.
BornG.V.R., KratzerM.A.A.Source and concentration of extracellular adenosine triphosphate during hemostasis in rats, rabbits and man.J Physiol1984; 354: 419–29.
5.
DukeW.W.The relation of blood platelets to hemorrhagic disease: description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion.JAMA1910; 55: 1185–92.
IvyA.C., NelsonD., BucherG.The standardization of certain factors in the cutaneous “venostasis” bleeding time technique.J Lab Clin Med1941; 26: 1812–22.
8.
BorchgrevinkC.F., WaalerB.A.The secondary bleeding time. A new method for the differentiation of hemorrhagic diseases.Acta Med Scand1958; 162: 361–74.
9.
MielkeC.H., KaneshiroM.M., MaherI.A., WeinerJ.M., RapaportS.I.The standardized normal Ivy bleeding time and its prolongation by aspirin.Blood1969; 34: 204–15.
MannucciP.M., RemuzziG., PusineriF.Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.N Engl J Med1983; 308: 8–12.
14.
LivioM., BenigniA., RemuzziG.Coagulation abnormalities in uremia.Semin Nephrol1985; 5: 82–90.
15.
KazatchkineM., SultanY., CaenJ.P., BarietyJ.Bleeding in renal failure: a possible cause.Br Med J1976; 2: 612–5.
16.
WarrellR.P., HultinM.B., CollerB.S.Increased factor VIII/-von Willebrand factor antigen and von Willebrand factor activity in renal failure.Am J Med1979; 66: 226–8.
17.
JansonP.A., JubelirerS.J., WeinsteinM.J., DeykinD.Treatment of the bleeding tendency in uremia with cryoprecipitate.N Engl J Med1980; 303: 1318–22.
18.
BabsonS.R., BabsonA.L.Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations.Am J Clin Pathol1978; 70: 406–8.
19.
KratzerM.A.A., BornG.V.R.Simulation of primary haemostasis in vitro.Haemostasis1985; 15: 357–62.
20.
MaurinN.Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.Arzneimittelforsch/Drug Res1986; 36(II): 1180–3.
21.
EknoyanG., WaksmanS.J., GlueckH.I., WillJ.J.Platelet function in renal failure.N Engl J Med1969; 280: 677–81.
22.
CastaldiP.A., RozenbergM.C., StewartJ.H.The bleeding disorder of uraemia. A qualitative platelet defect.Lancet1966; II: 66–9.
23.
LindsayR.M., FriesenM., AronstamA., AndrusF., ClarkW.F., LintonA.L.Improvement of platelet function by increased frequency of hemodialysis.Clin Nephrol1978; 10: 67–70.
24.
RemuzziG., LivioM., MarchiaroG., MeccaG., de GaetanoG.Bleeding in renal failure: altered platelet function in chronic uremia only partially corrected by haemodialysis.Nephron1978; 22: 347–53.
25.
ZusmanR.M., RubinR.H., CatoA.E., CocchettoD.M., CrowJ.W., Tolkoff-RubinN.Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.N Engl J Med1981; 304: 934–9.
26.
SmithM.C., DanviriyasupK., CrowJ.W.Prostacyclin substitution for heparin in long-term hemodialysis.Am J Med1982; 73: 669–78.
27.
MoncadaS., GryglewskiR., BuntingS., VaneJ.R.An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.Nature1976; 263: 663–5.
28.
HellemA.J., BorchgrevinkC.F., AmesS.B.The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesion.Br J Haematol1969; 7: 42–50.
29.
LivioM., GottiE., MarchesiD., MeccaG., RemuzziG., de GaetanoG.Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions.Lancet1982; II: 1013–5.
30.
FernandezF., GoudableC., SieP.Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions.Br J Haematol1985; 59: 139–48.
31.
MoiaM., MannucciP.M., VizzottoL., CasatiS., CattaneoM., PonticelliC.Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.Lancet1987; II: 1227–9.
32.
SchallenbergU., StillerS., MannH.A new method of continuous haemoglobinometric measurement of blood volume during haemodialysis.Life Support Syst1987; 5: 293–305.
33.
TurneyJ.H., WilliamsL.C., FewellM.R., ParsonsV., WestonM.J.Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.Lancet1980; II: 219–22.
